Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB)

被引：15
|
作者：
Hottinger, Andreas Felix
Sanson, Marc
Moyal, Elizabeth
Delord, Jean-Pierre
De Micheli, Rita
Rezai, Keyvan
Leung, Abraham C. F.
Perez, Susan
Bekradda, Mohamed
Lachaux, Nicolas
Lokiec, Francois Marc
Chinot, Olivier L.
机构：
[1] CHUV Univ Hosp, Lausanne, Switzerland
[2] Grp Hosp Univ Salpetriere, Paris, France
[3] IUCT O, Inst Claudius Regaud, Toulouse, France
[4] Inst Claudius Regaud, Toulouse, France
[5] CHU Vaudois, Lausanne, Switzerland
[6] Univ Lausanne Hosp, Lausanne, Switzerland
[7] Inst Curie Hop Rene Huguenin, St Cloud, France
[8] Genentech BioOnc, San Francisco, CA USA
[9] Merck Res Labs, Rahway, NJ USA
[10] Oncol Therapeut Dev, Clichy, France
[11] Aix Marseille Univ, Serv Neuro Oncol, AP HM, CHU Timone, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e14123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14123
引用
收藏
页数：2
相关论文
共 23 条
  • [21] Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (R/R) solid tumors.
    Piha-Paul, Sarina Anne
    Sachdev, Jasgit C.
    Barve, Minal A.
    LoRusso, Patricia
    Szmulewitz, Russell Zelig
    Patel, Sapna Pradyuman
    McKee, Mark D.
    Wolff, Johannes E.
    Hu, Beibei
    Sood, Anjla
    Chen, Xiaotian
    Wilson, Sarah C.
    O'Neil, Bert H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] First-In-Human Study of ABBV-075 (Mivebresib), A Pan-Inhibitor of Bromodomain and Extra Terminal (BET) Proteins, in Patients (Pts) With Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML): Preliminary Data
    Borthakur, Gautam
    Wolff, Johannes
    Aldoss, Ibrahim
    Hu, Beibei
    Minh Dinh
    Torres, Alison
    Chen, Xiaotian
    Rizzieri, David
    Sood, Anjla
    Odenike, Olatoyosi
    Jonas, Brian A.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S203 - S203
  • [23] First-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (RR) acute myeloid leukemia (AML): Preliminary data.
    Borthakur, Gautam
    Wolff, Johannes E.
    Aldoss, Ibrahim
    Hu, Beibei
    Minh Dinh
    Torres, Alison
    Chen, Xiaotian
    Rizzieri, David
    Sood, Anjla
    Odenike, Olatoyosi
    Jonas, Brian Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
123